Bictegravir/emtricitabine/tenofovir alafenamide, sold under the brand name Biktarvy, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. One tablet, taken orally once daily, contains 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide.[1] It was approved for use in the United States in February 2018,[2][3] and for use in the European Union in June 2018.[4]
Bictegravir (integrase inhibitor):
Emtricitabine (nucleotide reverse transcriptase inhibitor):
- .
- at reverse transcriptase (2no6). Water molecules are shown as red spheres.
Tenofovir alafenamide (nucleotide reverse transcriptase inhibitor):
